TABLE 5.

Details obtained from peripheral blood cell count performed at the start and last assessment while on biotechnological agents and JAKis.

	Start of treatment	Last assessment	p-value
Anti-IL-1
RBC, millions/mmc	3.7 ± 1.7	3.47 ± 0.69	0.87
Hb, g/dl	10.95 ± 1.8	11.42 ± 2.2	0.52
MCV, fl	105.4 ± 22.3	105.5 ± 14.8	0.99
WBC, n/mmc	4'668 ± 1′052	5'392 ± 2′445	0.53
Neutrophils (%)	65.35 ± 0.4	63.37 ± 31.4	0.92
Lymphocytes (%)	22.25 ± 2.47	29.30 ± 30.3	0.73
Platelets, n/mmc	185′500 ± 99013	123′500 ± 51427	0.21
Anti-IL-6
RBC, millions/mmc	3.0 ± 0.84	3.2 ± 0.38	0.67
Hb, g/dl	10.3 ± 2.3	10.9 ± 1.4	0.58
MCV, fl	104.6 ± 9.1	105.1 ± 6.6	0.91
WBC, n/mmc	5′166 ± 2′228	2′953 ± 1′032	0.04
Neutrophils (%)	61 ± 19.3	51 ± 22.4	0.43
Lymphocytes (%)	45.6 ± 22.1	41.4 ± 21.5	0.74
Platelets, n/mmc	119′371 ± 39’770	120′125 ± 73’892	0.98
Anti-TNF
RBC, millions/mmc	3.2 ± 0.7	3.1 ± 0.57	0.85
Hb, g/dl	10.25 ± 1	10.1 ± 1.3	0.9
MCV, fl	98 ± 17.5	102 ± 14.9	0.73
WBC, n/mmc	10′280 ± 9′111	10003 ± 7341	0.97
Neutrophils (%)	50 ± 19.5	56 ± 16.25	0.69
Lymphocytes (%)	42 ± 21.5	36 ± 16	0.71
Platelets, n/mmc	142′667 ± 24172	179′500 ± 106928	0.55
JAK inhibitor
RBC, millions/mmc	3′307′778 ± 710′700	2′909′333 ± 1′220′919	0.41
Hb, g/dl	10.9 ± 1.6	10.4 ± 1.4	0.48
MCV, fl	98 ± 8.4	101.3 ± 10.9	0.78
WBC, n/mmc	6′061 ± 3′605	3′950 ± 2′212	0.12
Neutrophils (%)	64.3 ± 24.1	64.8 ± 15.7	0.96
Lymphocytes (%)	53.5 ± 25	32.1 ± 14.5	0.055
Platelets, n/mmc	186′000 ± 108′999	219′250 ± 155′626	0.57

Abbreviations: Hb, hemoglobin (grams per deciliter); IL, interleukin; MCV, mean corpuscular volume (femtoliter); RBC, red blood cells (millions per cubic millimeter); TNF, tumor necrosis factor; WBC, white blood cells (number per cubic millimeter).